Survival analysis of joint replacement relies on the assumption that surgical procedures in patients lost to follow-up have the same chance of failing as those in patients who continue to be assessed. Our study questions that assumption.
It is expected that of patients undergoing joint replacement some will be lost to follow-up. In a survival analysis of joint replacement it is assumed that such patients have the same outcome as those who continue to be reviewed. 1, 2 Some of the patients lost to follow-up, however, may be dissatisfied with their treatment and stop attending clinics for this reason. [1] [2] [3] [4] [5] There is therefore probably a higher rate of failure in these patients than in those who continue to be followed up. Consequently, survival analysis, as currently performed, provides an over-optimistic picture of results.
In a recent review of survival analyses, the rate of loss to follow-up was quoted in only half of the papers reviewed and was approximately 5%. 2 In those which did not mention loss to follow-up, the rates were probably higher. The annual revision rate after joint replacement is approximately 1%. If the failure rate in the group lost to follow-up was markedly higher than in the group of patients who were assessed, little reliance can be placed on calculated survival rates. Dorey and Amstutz 1 suggested that these fears are groundless. They compared the results of two studies which reported the outcome of the same joint-replacement procedure. In the first study 45% of patients were lost to follow-up and in the second 10%. The calculated survival rates were the same in both studies and they concluded that loss to follow-up was not important and that assumptions made in the survival analyses about patients lost to follow-up were valid. This conclusion has been challenged on the grounds that the group of patients who were particularly unwilling to return for follow-up or who could not be traced may have included a high number of patients who were dissatisfied with the results of surgery. 6 Survival analyses assume that procedures in patients who are 'withdrawn' have the same chance of failure as those in patients who continue to be reviewed. The withdrawn group includes patients who reach the end of the trial, die or are lost to follow-up. The assumption that implants in patients who die during trials have the same annual failure rates as those in survivors has not previously been questioned. 2 At first sight this appears to be a reasonable assumption, but patients who die may not have been fit enough for surgery, and unsatisfactory implants may not have been revised, thus giving an over-optimistic picture of the results. To determine whether implants in patients who are lost to follow-up or die have the same outcome as in those who continue to be assessed, we have studied the outcome of total hip replacement (THR) in two groups of patients, those in whom vigorous and repeated attempts to obtain follow-up data were unsuccessful and in those who died.
PATIENTS AND METHODS
We have reanalysed data obtained from the follow-up of 2268 patients who had undergone THR between 1967 and 1989 at one centre. 7, 8 Patients had been reviewed at six months and one year after the procedure and then at every two years for up to 16 years. At each review the level of pain, range of movement and progress as judged by the patient were recorded on a scale of 1 to 6; radiographs were also taken and graded from 1 to 3 (Table I) . During this time 142 (6.3%) patients failed to respond to repeated requests for attendance and 444 (19.6%) died. To determine whether these patients differed from those who continued to attend clinic, their last recorded assessment was examined. At six months, eight patients had been lost to follow-up and 40 had died. As no previous assessments were recorded for these patients they were excluded from their part of the study. Non-attenders were matched with the next two patients in the database who attended subsequent clinics and the outcomes were compared. The database was ordered according to date of procedure. A similar investigation was undertaken for those patients who died but, as the number was much higher, they were matched with only one control.
Possible baseline differences between attenders and nonattenders were compared. To assess the differences in outcome after THR, we used the Wilcoxon matched-pairs signed-rank test to compare the last recorded assessment of non-attenders with the assessments of their matched controls. Patients who died were compared with matched controls in the same way.
To determine the cumulative rates of follow-up and loss to follow-up a survival analysis was undertaken in which non-attenders were classified as failures and patients who had been successfully followed up as successes including those who had died or had revised implants. The life-table method was used and 95% confidence limits (CL) were determined using the Peto equation. 9 
RESULTS
Rates of follow-up for each year after THR were determined by survival analysis and are shown with the overall follow-up rate in Figure 1 . The cumulative rate was 94.6% (CL 93.4% to 95.8%) at 5 years and 80.4% (CL 70.7% to 90.1%) at 15 years. The cumulative rate of loss to followup was 5.4% at 5 years and 19.6% at 15 years, despite the overall rate being 6.3%. No significant differences were found between attenders and non-attenders in terms of diagnosis, age or gender (Table II) . Patients who had been operated on by a consultant were slightly, although not significantly (p = 0.07), more likely to be lost to follow-up than those who had been operated on by other grades (6.7% v 4.3%). At their last recorded attendance non-attenders had highly significantly There was a marked increase in the number of patients with significant symptoms and poor radiographs in the group lost to follow-up (Table III) . Twice as many patients who were subsequently lost to follow-up had moderate pain compared with those who continued to attend, five times as many had poor movement, nine times as many thought their outcome was fair or poor, and three times as many had deteriorating radiographs. No significant differences were found between the last recorded assessment of patients who had died and their matched controls (Table IV) .
DISCUSSION
These results clearly show that patients lost to follow-up have a worse outcome than those who are not lost. Many more patients in the lost-to-follow-up group had significant symptoms and deteriorating radiographs than in the group who continued to attend for review. Before an implant fails and is revised symptoms progressively worsen and radiological appearances deteriorate. 7 Thus, the chance of implants failing in patients who are not followed up is likely to be substantially higher than in those who continue to be assessed. Consequently, failed implants in patients who are lost will be missed and study results will be falsely optimistic. This has important implications for the assessment of joint replacement since so few implants fail and if some failures are missed the results become meaningless. It is essential that loss to follow-up should be minimised and accurately quantified, and that the possible consequences highlighted.
The magnitude of the problem of loss to follow-up will be disguised if loss to follow-up is merely quantified by an overall rate. In our study, the cumulative rate at 15 years (20%) was three times greater than the overall rate (6%) (Fig. 1) . We recommend that in survival analyses the cumulative rate of loss to follow-up should be calculated and quoted. To calculate the cumulative rate, loss to followup should be used as the definition of failure. If the cumulative follow-up rate is substantially lower than the cumulative survival rate little reliance can be placed on the latter.
In a survival analysis it is assumed that patients lost to follow-up have the same chance of failure as those who continue to be assessed. This does not allow for those patients who fail to attend as a result of poor outcome. It is therefore important to have a technique to quantify the magnitude of this bias. One solution is to plot a worst-case survival curve 2 which is derived by assuming that implants in all patients lost to follow-up have failed and have been revised. Although the true survival curve is not as low as the worst-case curve, it gives an indication of how much the 
Standard survival curve compared with the worst-case curve, which is calculated by assuming that patients lost to follow-up had failed implants.
results would have been degraded if patients lost to followup had subsequently become failures. A worst-case curve has been plotted for the patients in our study (Fig. 2) , 7, 8 and even although rate of loss to follow-up is relatively low, this curve degrades the results substantially. In studies with a higher loss to follow-up the results would be degraded to such an extent as to make them meaningless. 2 As the worstcase curve, which relates to loss to follow-up, and confidence limits, which relate to small numbers, quantify different problems, both should be calculated. When two treatments are compared, it is important to make sure that loss to follow-up in both groups is small and not statistically different (using the log-rank test).
The last recorded assessment for the patients who died was similar to that of the matched controls, indicating a similar outcome in the two groups. The techniques used for analysing data from patients who die during a study are therefore valid. If two treatments are being compared it is probably justifiable to carry out such an analysis, even if the death rates of the two groups are different.
Our study refutes the view of Dorey and Amstutz 1 that loss to follow-up does not matter. In our study we expected a high rate of failure in the 6% of patients who did not attend for follow-up. As the rate of loss to follow-up in both Dorey and Amstutz trials was substantially greater than 6%, we would not necessarily have expected a comparison between their trials to have identified the problem of loss to follow-up. Two important conclusions can be drawn from our study: first, failures are missed in many series because patients with problems are likely to avoid follow-up, and, secondly, by the end of a trial the cumulative loss to follow-up is many times greater than the overall loss. In most survival analyses of joint replacement, both the overall loss to follow-up and the cumulative rate of failure are 5% to 10%. The cumulative loss to follow-up is therefore much higher than the cumulative rate of failure, suggesting that in the most trials little reliance can be placed on the calculated rates.
A simple way to assess the reliability of a survival analysis is to compare the number of patients lost to followup with the number of failures. This is best quantified by a loss-to-follow-up quotient, calculated by dividing the number lost by the number of failures: the lower the quotient the more reliable the data. If the quotient is greater than 1, meaning that more patients are lost than fail, then little reliance can be placed on calculated survival rates.
